Sugi Predict

Sugi Predict / Compounds / SCHEMBL7120215

SCHEMBL7120215

SCHEMBL7120215

O=[C]Oc1ccccc1C(=O)C(=O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 11/20 0.50
▸ CES1 P23141 10/20 0.50
▸ SLC6A3 Q01959 1/20 0.40
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ ELANE P08246 1/20 0.38
▸ AKR1C3 P42330 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ MAPT P10636 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ ESR1 P03372 1/20 0.37
▸ ITGB3 P05106 1/20 0.37
▸ ITGA2B P08514 1/20 0.37
▸ HMGB1 P09429 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ GGT1 P19440 1/20 0.37
▸ PTGS1 P23219 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5633418 0.84 ELANE (0.54) RAB9AELANEAKR1C3KDM4EALDH1A1
SCHEMBL3835294 0.81 KDM4E (0.55) AKR1C3KDM4EALDH1A1MAPTKMT2A
SCHEMBL4197049 0.81 CES2 (0.58) CES2CES1SLC6A3NPC1RAB9A
SCHEMBL6832601 0.79 CES2 (0.56) CES2CES1SLC6A3NPC1RAB9A
SCHEMBL5704292 0.78 RAB9A (0.62) CES2CES1SLC6A3NPC1RAB9A
SCHEMBL11508105 0.76 CTNNB1 (0.62) CES2CES1RAB9AAKR1C3ALDH1A1
SCHEMBL5666795 0.76 CES2 (0.52) CES2CES1SLC6A3NPC1RAB9A
SCHEMBL4579639 0.76 HTT (0.61) CES2CES1AKR1C3KDM4EALDH1A1
SCHEMBL6863551 0.76 CES2 (0.52) CES2CES1SLC6A3NPC1RAB9A
SCHEMBL8574337 0.76 CES2 (0.78) CES2CES1RAB9AAKR1C3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10954257-B2 Prodrugs of glutamine analogs THE JOHNS HOPKINS UNIVERSITY (US) 2021-03-23 — — US disclosed
US-10738066-B2 Prodrugs of glutamine analogs THE JOHNS HOPKINS UNIVERSITY (US) 2020-08-11 — — US disclosed
US-20190315784-A1 PRODRUGS OF GLUTAMINE ANALOGS DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT 2019-10-17 — — US disclosed
US-20190315783-A1 PRODRUGS OF GLUTAMINE ANALOGS DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT 2019-10-17 — — US disclosed
US-20030207432-A1 Remedies for intractable wound FUJISAWA PHARMACEUTICAL CO., LTD., (JP) 2003-11-06 — — US disclosed
EP-1230933-A1 REMEDIES FOR INTRACTABLE WOUND FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-08-14 — — EP disclosed
EP-0347235-A2 Photosensitive silver halide color photographic material KONICA CORPORATION (JP) 1989-12-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738066-B2 Prodrugs of glutamine analogs GLUL, GLS, GLS2 CES2 2286/4885CES1 1249/4885SLC6A3 422/4885
US-20190315783-A1 PRODRUGS OF GLUTAMINE ANALOGS GLUL, GLS, GLS2 CES2 2286/4885CES1 1249/4885SLC6A3 422/4885
US-10954257-B2 Prodrugs of glutamine analogs GLUL, GLS, GLS2 CES2 2286/4885CES1 1249/4885SLC6A3 422/4885
US-20190315784-A1 PRODRUGS OF GLUTAMINE ANALOGS GLUL, GLS, GLS2 CES2 2286/4885CES1 1249/4885SLC6A3 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.